SEK 37.65
(2.45%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | 311 Thousand EUR | 87.35% |
2022 | 166 Thousand EUR | 21.17% |
2021 | 137 Thousand EUR | -24.73% |
2020 | 182 Thousand EUR | -29.46% |
2019 | 258 Thousand EUR | 69.74% |
2018 | 151.99 Thousand EUR | 178.85% |
2017 | 54.5 Thousand EUR | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | 214 Thousand EUR | -31.19% |
2024 Q2 | 181 Thousand EUR | -15.42% |
2023 Q1 | 158 Thousand EUR | -4.82% |
2023 Q3 | 253 Thousand EUR | -2.32% |
2023 FY | 311 Thousand EUR | 87.35% |
2023 Q4 | 311 Thousand EUR | 22.92% |
2023 Q2 | 259 Thousand EUR | 63.92% |
2022 Q1 | 216 Thousand EUR | 57.66% |
2022 Q2 | 122 Thousand EUR | -43.52% |
2022 Q3 | 152 Thousand EUR | 24.59% |
2022 Q4 | 166 Thousand EUR | 9.21% |
2022 FY | 166 Thousand EUR | 21.17% |
2021 Q3 | 149 Thousand EUR | 10.37% |
2021 Q1 | 167 Thousand EUR | -8.24% |
2021 Q2 | 135 Thousand EUR | -19.16% |
2021 FY | 137 Thousand EUR | -24.73% |
2021 Q4 | 137 Thousand EUR | -8.05% |
2020 Q1 | - EUR | -100.0% |
2020 Q3 | 263 Thousand EUR | -1.73% |
2020 Q2 | 267.62 Thousand EUR | 0.0% |
2020 FY | 182 Thousand EUR | -29.46% |
2020 Q4 | 182 Thousand EUR | -30.8% |
2019 FY | 258 Thousand EUR | 69.74% |
2019 Q4 | 258 Thousand EUR | 0.0% |
2018 FY | 151.99 Thousand EUR | 178.85% |
2017 FY | 54.5 Thousand EUR | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Acarix AB (publ) | 6.83 Million SEK | 95.453% |
ADDvise Group AB (publ) | 121.2 Million SEK | 99.743% |
ADDvise Group AB (publ) | 121.2 Million SEK | 99.743% |
Arcoma AB | 28.02 Million SEK | 98.89% |
Bactiguard Holding AB (publ) | 29.64 Million SEK | 98.951% |
BICO Group AB (publ) | 493.1 Million SEK | 99.937% |
Boule Diagnostics AB (publ) | 62.4 Million SEK | 99.502% |
CellaVision AB (publ) | 126.03 Million SEK | 99.753% |
Clinical Laserthermia Systems AB (publ) | 6.11 Million SEK | 94.914% |
Chordate Medical Holding AB (publ) | 1.77 Million SEK | 82.439% |
C-Rad AB (publ) | 64.09 Million SEK | 99.515% |
Duearity AB (publ) | 4.15 Million SEK | 92.522% |
Dignitana AB (publ) | 7.41 Million SEK | 95.805% |
Episurf Medical AB (publ) | 3.7 Million SEK | 91.595% |
Getinge AB (publ) | 6.41 Billion SEK | 99.995% |
Scandinavian Real Heart AB (Publ) | -1.68 Million SEK | 118.475% |
Iconovo AB (publ) | -4.86 Million SEK | 106.397% |
Integrum AB (publ) | 22.36 Million SEK | 98.609% |
Luxbright AB (publ) | 8000.00 SEK | -3787.5% |
Mentice AB (publ) | 14.1 Million SEK | 97.795% |
OssDsign AB (publ) | 4.3 Million SEK | 92.774% |
Paxman AB (publ) | 19.99 Million SEK | 98.445% |
Promimic AB (publ) | 330 Thousand SEK | 5.758% |
Qlife Holding AB (publ) | 7.29 Million SEK | 95.735% |
SciBase Holding AB (publ) | 11.91 Million SEK | 97.391% |
ScandiDos AB (publ) | 22.69 Million SEK | 98.629% |
Sectra AB (publ) | 36.59 Million SEK | 99.15% |
Sedana Medical AB (publ) | 42.97 Million SEK | 99.276% |
Senzime AB (publ) | 20.34 Million SEK | 98.471% |
SpectraCure AB (publ) | 1.00 SEK | -31099900.0% |
Stille AB | 66.55 Million SEK | 99.533% |
Vitrolife AB (publ) | 413 Million SEK | 99.925% |
Xvivo Perfusion AB (publ) | 141.6 Million SEK | 99.78% |